Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial
Official title:
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy Among Patients Attending Neuropsychiatry Department - Assiut University
Verified date | January 2022 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Chronic dysimmune neuropathies (CDN) are a heterogenous group of acquired inflammatory demyelinating neuropathies including chronic inflammatory demyelinating polyneuropathies (CIDP), Lewis-Sumner Syndrome (LSS), multifocal motor neuropathy (MMN) and other rare entities. Despite their relatively low prevalence, CDN lead to substantial costs for patients and society. CDN are usually misdiagnosed due to progressive nature of the disease with little known data regarding disease activity and treatment response
Status | Not yet recruiting |
Enrollment | 36 |
Est. completion date | December 2026 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age > 18 years, both sexes, history of sensory and/or motor complaint with progressive course over more 2 months Exclusion Criteria: - *Patients with systemic diseases (DM, chronic kidney or liver disease, thyroid disease, vitamin B12 deficiency) - Family history of peripheral neuropathy or neurological symptoms suggestive for heredo-familial neurological disorders - Patients with infective cause as (HBV, HCV, HIV, leprosy) - Toxic and drug induced polyneuropathy (chemotherapeutics, antimicrobial .. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Breiner A, Brannagan TH 3rd. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014 Jul;50(1):40-6. doi: 10.1002/mus.24088. Epub 2013 Dec 11. — View Citation
Hartung HP, Lehmann HC, Willison HJ. Peripheral neuropathies: Establishing common clinical research standards for CIDP. Nat Rev Neurol. 2011 May;7(5):250-1. doi: 10.1038/nrneurol.2011.46. Epub 2011 Apr 12. — View Citation
Rajabally YA, Nicolas G, Piéret F, Bouche P, Van den Bergh PY. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry. 2009 Dec;80(12):1364-8. doi: 10.1136/jnnp.2009.179358. Epub 2009 Jul 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients diagnosed with chronic inflammatory demyleinating polyneuropathy attending neuropsychiatry department Assiut university | Number of patients diagnosed with chronic inflammatory demyleinating polyneuropathy attending neuropsychiatry department Assiut university | From January 2023 to December 2026 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02465359 -
Subcutaneous Immunoglobulin for CIDP
|
N/A | |
Recruiting |
NCT05584631 -
IVIG vs SCIG in CIDP
|
Phase 1 | |
Withdrawn |
NCT01236456 -
High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
Terminated |
NCT03779828 -
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
|
||
Completed |
NCT01184846 -
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT05011006 -
NT-3 Levels and Function in Individuals With CMT
|
||
Recruiting |
NCT06290141 -
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
Completed |
NCT01379833 -
Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
|
||
Completed |
NCT02414490 -
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
|
||
Completed |
NCT01545076 -
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
|
Phase 3 | |
Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
Recruiting |
NCT04672733 -
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
|
||
Not yet recruiting |
NCT04480450 -
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
Completed |
NCT02111590 -
Immunoglobulin Dosage and Administration Form in CIDP and MMN
|
N/A | |
Recruiting |
NCT04292834 -
A Registered Cohort Study of Immune-Mediated Neuropathies
|
||
Terminated |
NCT03772717 -
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
N/A | |
Completed |
NCT00278629 -
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 | |
Recruiting |
NCT02372149 -
IVIg for Demyelination in Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT00962429 -
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 2 |